Showing results (171-180 of 370) with videos related to

Sort By:
Pageof 37
The New Phytologist|March 7, 2026
Functional uncoupling of the induced defense-competitive growth trade-offMichael B Mueller, Xueying Chen, Casey S Philbin, et al.
Journal of Palliative Care|January 1, 1997
Family members' care expectations, care perceptions, and satisfaction with advanced cancer care: results of a multi-site pilot studyL J Kristjanson, A Leis, P M Koop, et al.
Spine|March 12, 2021
The Utility of Prolonged Prophylactic Systemic Antibiotics (PPSA) for Subfascial Drains After Degenerative Spine SurgeryGnel Pivazyan, William Mualem, Matthew R D'Antuono, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1993
Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseG Maass, U Immendoerfer, B Koenig, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 9, 2001
Psychophysiological responses in ADHD boys with and without conduct disorder: implications for adult antisocial behaviorS C Herpertz, B Wenning, B Mueller, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 3, 2003
Autonomic responses in boys with externalizing disordersS C Herpertz, B Mueller, B Wenning, et al.
Arquivos Do Instituto Biologico|July 1, 1978
[Isolation and identification of the infectious bovine rhinotracheitis virus in a bovine fetus kidney (IBR/IPV)]S B Mueller, A A Ikuno, M Teresa, et al.
The European Respiratory Journal|July 3, 2010
Prognostic value of procalcitonin in community-acquired pneumoniaP Schuetz, I Suter-Widmer, A Chaudri, et al.
Experimental and Molecular Pathology|June 1, 1991
Dietary and mechanically induced rabbit iliac-femoral atherosclerotic lesions: a chemical and morphologic evaluationT M Bocan, S B Mueller, P D Uhlendorf, et al.
Annals of the Rheumatic Diseases|June 29, 2014
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phaseMichael H Schiff, Johannes von Kempis, Ronald Goldblum, et al.
Pageof 37